Published in Antimicrob Agents Chemother on December 01, 1989
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1990) 1.66
MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires' disease. Infect Immun (2006) 1.65
Intraphagocytic growth induces an antibiotic-resistant phenotype of Legionella pneumophila. Antimicrob Agents Chemother (1995) 1.63
In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother (1999) 1.47
In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother (1991) 1.31
Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1996) 1.30
Pore formation triggered by Legionella spp. is an Nlrc4 inflammasome-dependent host cell response that precedes pyroptosis. Infect Immun (2010) 1.17
Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (2003) 1.14
Cooperation between multiple microbial pattern recognition systems is important for host protection against the intracellular pathogen Legionella pneumophila. Infect Immun (2010) 1.13
Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother (1994) 1.04
Multiple MyD88-dependent responses contribute to pulmonary clearance of Legionella pneumophila. Cell Microbiol (2008) 1.02
In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1992) 1.01
In vitro activity of Ro 23-9424 against clinical isolates of Legionella species. Antimicrob Agents Chemother (1992) 0.96
Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease. Antimicrob Agents Chemother (1991) 0.93
In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Antimicrob Agents Chemother (1994) 0.90
Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1. Antimicrob Agents Chemother (1990) 0.87
In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (2001) 0.84
lvgA, a novel Legionella pneumophila virulence factor. Infect Immun (2003) 0.84
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (2001) 0.83
In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results. Antimicrob Agents Chemother (2000) 0.82
In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species. Antimicrob Agents Chemother (1993) 0.81
Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. J Clin Microbiol (1997) 0.79
In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila. Antimicrob Agents Chemother (2005) 0.79
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Antimicrob Agents Chemother (2011) 0.78
Improved semiselective medium for isolation of Legionella pneumophila from contaminated clinical and environmental specimens. J Clin Microbiol (1981) 11.09
Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest (1983) 3.79
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother (1985) 2.87
Legionella infections: a review of five years of research. Rev Infect Dis (1983) 2.30
Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am Rev Respir Dis (1984) 2.18
Influence of growth temperature on virulence of Legionella pneumophila. Infect Immun (1987) 1.88
Susceptibility of Legionella spp. to mycinamicin I and II and other macrolide antibiotics: effects of media composition and origin of organisms. Antimicrob Agents Chemother (1982) 1.68
Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother (1986) 1.52
The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother (1986) 1.51
Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother (1986) 1.35
Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob Agents Chemother (1987) 1.35
Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J Infect Dis (1984) 1.34
Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media. J Antimicrob Chemother (1985) 1.30
Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. J Antimicrob Chemother (1989) 1.30
Studies on ciprofloxacin therapy of experimental Legionnaires' disease. J Infect (1985) 1.28
Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J Antimicrob Chemother (1988) 1.27
Antimicrobial susceptibility of intracellular Legionella pneumophila. Antimicrob Agents Chemother (1981) 1.22
Antibiotic susceptibility of Legionella pneumophia Philadelphia-1 in cultured guinea-pig peritoneal macrophages. J Gen Microbiol (1984) 1.14
The effect of antibiotics on the growth of Legionella pneumophila in guinea-pig alveolar phagocytes infected in vivo by an aerosol. J Infect (1985) 1.09
Comparative efficacy of five antibiotics on experimental airborne legionellosis in guinea-pigs. J Antimicrob Chemother (1988) 0.87
Immunologic diagnosis of Legionnaires' disease: cross-reactions with anaerobic and microaerophilic organisms and infections caused by them. J Infect Dis (1980) 2.76
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1990) 1.66
Discovery of virulence genes of Legionella pneumophila by using signature tagged mutagenesis in a guinea pig pneumonia model. Proc Natl Acad Sci U S A (1999) 1.65
Evaluation of the Merifluor-Legionella immunofluorescent reagent for identifying and detecting 21 Legionella species. J Clin Microbiol (1989) 1.64
Bacteroides gracilis, an important anaerobic bacterial pathogen. J Clin Microbiol (1985) 1.60
Comparison of different agars used in the formulation of buffered charcoal yeast extract medium. J Clin Microbiol (1991) 1.50
In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother (1999) 1.47
Comparison of three buffers used in the formulation of buffered charcoal yeast extract medium. J Clin Microbiol (1993) 1.38
In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother (1991) 1.31
Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1996) 1.30
In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother (1996) 1.10
Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother (1994) 1.04
The intraocular environment and experimental anaerobic bacterial endophthalmitis. Arch Ophthalmol (1987) 1.02
In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1992) 1.01
In vitro activity of Ro 23-9424 against clinical isolates of Legionella species. Antimicrob Agents Chemother (1992) 0.96
Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor. Antimicrob Agents Chemother (1987) 0.91
In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Antimicrob Agents Chemother (1994) 0.90
In vitro activity of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp. Diagn Microbiol Infect Dis (2000) 0.88
In vitro activity of SCH 27899 (Ziracin) against Legionella species. Diagn Microbiol Infect Dis (1999) 0.88
Intracellular growth of Legionella pneumophila serogroup 1 monoclonal antibody type 2 positive and negative bacteria. Epidemiol Infect (1993) 0.85
In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (2001) 0.84
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (2001) 0.83
Chronic anaerobic bacterial endophthalmitis in pseudophakic rabbit eyes. Invest Ophthalmol Vis Sci (1987) 0.82
Bacteriologic and clinical study of Bacteroides oris and Bacteroides buccae. J Clin Microbiol (1987) 0.81
BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. J Antimicrob Chemother (2001) 0.81
In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species. Antimicrob Agents Chemother (1993) 0.81
In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains. Diagn Microbiol Infect Dis (1989) 0.79
Anaerobic bacterial endophthalmitis in the rabbit. Invest Ophthalmol Vis Sci (1986) 0.77
Natamycin as a selective antifungal agent in media for growth of Legionella spp. J Clin Microbiol (1996) 0.77